Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease

Seung Hun Lee, Mi Jung Kim, Beom Jun Kim, Sung Reul Kim, Sail Chun, Jin Sook Ryu, Ghi Su Kim, Myoung Chong Lee, Jung Min Koh, Sun Ju Chung

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We investigated whether homocysteine (Hcy)-lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 μg vitamin B 12 daily), α-lipoic acid (α-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the α-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the α-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% ± 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 ± 0.024 ng/mL) than control group (0.628 ± 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.

Original languageEnglish
Pages (from-to)332-340
Number of pages9
JournalMovement Disorders
Volume25
Issue number3
DOIs
Publication statusPublished - 2010 Feb 15
Externally publishedYes

Fingerprint

Homocysteine
Parkinson Disease
Antioxidants
Bone and Bones
Bone Density
Levodopa
Group Psychotherapy
Femur
Control Groups
Therapeutics
Thioctic Acid
Vitamin B 12
Folic Acid
Spine
Body Mass Index
Serum

Keywords

  • Folate
  • Homocysteine
  • Osteoporosis
  • Parkinson's disease
  • Vitamin B

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Lee, S. H., Kim, M. J., Kim, B. J., Kim, S. R., Chun, S., Ryu, J. S., ... Chung, S. J. (2010). Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Movement Disorders, 25(3), 332-340. https://doi.org/10.1002/mds.22866

Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. / Lee, Seung Hun; Kim, Mi Jung; Kim, Beom Jun; Kim, Sung Reul; Chun, Sail; Ryu, Jin Sook; Kim, Ghi Su; Lee, Myoung Chong; Koh, Jung Min; Chung, Sun Ju.

In: Movement Disorders, Vol. 25, No. 3, 15.02.2010, p. 332-340.

Research output: Contribution to journalArticle

Lee, SH, Kim, MJ, Kim, BJ, Kim, SR, Chun, S, Ryu, JS, Kim, GS, Lee, MC, Koh, JM & Chung, SJ 2010, 'Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease', Movement Disorders, vol. 25, no. 3, pp. 332-340. https://doi.org/10.1002/mds.22866
Lee, Seung Hun ; Kim, Mi Jung ; Kim, Beom Jun ; Kim, Sung Reul ; Chun, Sail ; Ryu, Jin Sook ; Kim, Ghi Su ; Lee, Myoung Chong ; Koh, Jung Min ; Chung, Sun Ju. / Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. In: Movement Disorders. 2010 ; Vol. 25, No. 3. pp. 332-340.
@article{747c7bc301ad434f9969b28b42f341a5,
title = "Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease",
abstract = "We investigated whether homocysteine (Hcy)-lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 μg vitamin B 12 daily), α-lipoic acid (α-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4{\%}), total femur (2.8{\%}), and femur shaft (2.8{\%}) than control (P = 0.005-0.023). BMD changes in the α-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6{\%}) were significantly greater in the α-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2{\%} ± 13.4{\%} in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 ± 0.024 ng/mL) than control group (0.628 ± 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.",
keywords = "Folate, Homocysteine, Osteoporosis, Parkinson's disease, Vitamin B",
author = "Lee, {Seung Hun} and Kim, {Mi Jung} and Kim, {Beom Jun} and Kim, {Sung Reul} and Sail Chun and Ryu, {Jin Sook} and Kim, {Ghi Su} and Lee, {Myoung Chong} and Koh, {Jung Min} and Chung, {Sun Ju}",
year = "2010",
month = "2",
day = "15",
doi = "10.1002/mds.22866",
language = "English",
volume = "25",
pages = "332--340",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease

AU - Lee, Seung Hun

AU - Kim, Mi Jung

AU - Kim, Beom Jun

AU - Kim, Sung Reul

AU - Chun, Sail

AU - Ryu, Jin Sook

AU - Kim, Ghi Su

AU - Lee, Myoung Chong

AU - Koh, Jung Min

AU - Chung, Sun Ju

PY - 2010/2/15

Y1 - 2010/2/15

N2 - We investigated whether homocysteine (Hcy)-lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 μg vitamin B 12 daily), α-lipoic acid (α-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the α-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the α-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% ± 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 ± 0.024 ng/mL) than control group (0.628 ± 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.

AB - We investigated whether homocysteine (Hcy)-lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty-two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy-lowering therapy (5 mg folate and 1500 μg vitamin B 12 daily), α-lipoic acid (α-LA) therapy (1200 mg daily), or control groups. Primary outcomes were BMD changes from baseline to 12 months. Secondary outcomes were changes in Hcy level, and C-telopeptide (CTX) levels at 12 months. Forty-one patients completed the study. Hcy-lowering therapy resulted in significantly greater BMD changes at the lumbar spine (4.4%), total femur (2.8%), and femur shaft (2.8%) than control (P = 0.005-0.023). BMD changes in the α-LA therapy group were similar to those of the control group, but changes at the trochanter (4.6%) were significantly greater in the α-LA therapy group than in the control group after adjustment for body mass index changes. Hcy concentrations decreased to 35.2% ± 13.4% in the Hcy-lowering therapy group, but increased in other groups. Serum CTX levels at 12 months tended to be lower in the Hcy-lowering group (0.442 ± 0.024 ng/mL) than control group (0.628 ± 0.039 ng/mL) (P = 0.159). This small trial suggests that Hcy-lowering therapy may prevent bone loss in PD patients taking levodopa.

KW - Folate

KW - Homocysteine

KW - Osteoporosis

KW - Parkinson's disease

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=77649158888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649158888&partnerID=8YFLogxK

U2 - 10.1002/mds.22866

DO - 10.1002/mds.22866

M3 - Article

VL - 25

SP - 332

EP - 340

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 3

ER -